Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?

Area of Science:

• Oncology
• Immunotherapy
• Prostate Cancer Research

Background:

• Prostate cancer (PCa) is a leading neoplasm with evolving treatments.
• Advanced PCa progresses to metastatic castration-resistant stages, necessitating novel therapies.
• Current immunotherapies, including immune checkpoint inhibitors, have yielded suboptimal results in PCa.

Purpose of the Study:

• To review and discuss the potential reasons for the limited efficacy of immune checkpoint inhibitors in prostate cancer.
• To analyze factors contributing to the disappointing clinical outcomes of immunotherapy in PCa.
• To provide insights into overcoming immunotherapy challenges in advanced prostate cancer.

Main Methods:

• Literature review of clinical trials and preclinical studies on immunotherapy in prostate cancer.
• Analysis of factors influencing immune response in the tumor microenvironment of PCa.
• Comparative assessment of immunotherapy efficacy across different cancer types.

Main Results:

• Immune checkpoint inhibitors have not significantly improved progression-free or overall survival in prostate cancer patients.
• Consistently disappointing results contrast with successes in other tumor types.
• Several biological and clinical factors may underlie the limited response to immunotherapy in PCa.

Conclusions:

• Further research is needed to understand the specific barriers to effective immunotherapy in prostate cancer.
• Strategies to enhance immune response and overcome resistance mechanisms are crucial for improving PCa treatment outcomes.
• Identifying and addressing the reasons for immunotherapy failure is essential for developing more effective treatments for advanced prostate cancer.